NL8600555A - Farmaceutische formuleringen en werkwijze voor de behandeling van geheugenstoornissen. - Google Patents

Farmaceutische formuleringen en werkwijze voor de behandeling van geheugenstoornissen. Download PDF

Info

Publication number
NL8600555A
NL8600555A NL8600555A NL8600555A NL8600555A NL 8600555 A NL8600555 A NL 8600555A NL 8600555 A NL8600555 A NL 8600555A NL 8600555 A NL8600555 A NL 8600555A NL 8600555 A NL8600555 A NL 8600555A
Authority
NL
Netherlands
Prior art keywords
formula
compound
formulation according
lower alkyl
represent hydrogen
Prior art date
Application number
NL8600555A
Other languages
English (en)
Dutch (nl)
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of NL8600555A publication Critical patent/NL8600555A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NL8600555A 1985-03-05 1986-03-04 Farmaceutische formuleringen en werkwijze voor de behandeling van geheugenstoornissen. NL8600555A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/708,466 US4680172A (en) 1985-03-05 1985-03-05 Devices and methods for treating memory impairment
US70846685 1985-03-05

Publications (1)

Publication Number Publication Date
NL8600555A true NL8600555A (nl) 1986-10-01

Family

ID=24845894

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8600555A NL8600555A (nl) 1985-03-05 1986-03-04 Farmaceutische formuleringen en werkwijze voor de behandeling van geheugenstoornissen.

Country Status (17)

Country Link
US (1) US4680172A (ja)
JP (2) JPH0780769B2 (ja)
AT (1) ATA55386A (ja)
AU (1) AU5427586A (ja)
BE (1) BE904342A (ja)
CA (1) CA1274175A (ja)
CH (1) CH667993A5 (ja)
DE (1) DE3606892A1 (ja)
DK (1) DK99086A (ja)
FR (2) FR2578421B1 (ja)
GB (1) GB2171906B (ja)
IL (1) IL78025A0 (ja)
IT (1) IT1208735B (ja)
LU (1) LU86324A1 (ja)
NL (1) NL8600555A (ja)
SE (2) SE8600947L (ja)
ZA (1) ZA861582B (ja)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
US4666926A (en) * 1986-02-27 1987-05-19 Warner-Lambert Company Transdermal formulations
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US4791107A (en) * 1986-07-16 1988-12-13 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4808414A (en) * 1986-09-29 1989-02-28 Nelson Research & Development Co. Amide penetration enhancers for transdermal delivery of systemic agents
DE3639418A1 (de) * 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
US5187165A (en) * 1987-05-15 1993-02-16 Hoechst-Roussel Pharmaceuticals Inc. Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
US4788064A (en) * 1987-07-31 1988-11-29 Warner-Lambert Company Transdermal delivery system
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US5834011A (en) * 1988-02-19 1998-11-10 The Regents Of The University Of California Method for aiding in the reduction of incidence of tobacco smoking
US5364630A (en) * 1988-06-14 1994-11-15 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
DE3843239C1 (ja) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (ja) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
IE62662B1 (en) * 1989-01-06 1995-02-22 Elan Corp Plc Use of nicotine in the treatment of conditions susceptible to said treatment
CA2012192A1 (en) * 1989-03-28 1990-09-28 Munir A. Hussain Intranasal administration of physostigmine and arecoline
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5177101A (en) * 1989-11-30 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine
US5077289A (en) * 1989-11-30 1991-12-31 Hoechst Roussel Pharmaceuticals Inc. Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine
US5077104A (en) * 1989-12-21 1991-12-31 Alza Corporation Nicotine packaging materials
US4983616A (en) * 1990-02-01 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Hexahydropyrrolo(2,3-B)indole carbamates, ureas, amides and related compounds
US5508038A (en) * 1990-04-16 1996-04-16 Alza Corporation Polyisobutylene adhesives for transdermal devices
HU207444B (en) * 1990-07-12 1993-04-28 Biorex Kutato Fejlesztoe Kft Method for producing therapeutical preparation suitable for treating alzheimer-disease
KR0175638B1 (ko) * 1991-03-01 1999-02-18 카렌 에이.홀브루크 신경계 퇴행성 질환 치료용 니코틴 아날로그의 개량된 제조방법
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
US6205654B1 (en) 1992-12-11 2001-03-27 Staktek Group L.P. Method of manufacturing a surface mount package
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5731314A (en) * 1995-01-06 1998-03-24 Bencherif; Merouane Pharamceutical compositions for prevention and treatment of tourette's syndrome
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
DE19605590A1 (de) 1996-02-15 1997-08-21 Inresa Arzneimittel Gmbh Verwendung eines transdermalen therapeutischen Naloxon-Systems (Naloxon TTS)
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
EP0894799B1 (en) * 1997-01-16 2004-04-07 Toray Industries, Inc. Indolomorphinane derivatives and remedies/preventives for cerebral disorders
DE19847715A1 (de) * 1998-10-16 2000-04-20 Lohmann Therapie Syst Lts Verfahren zur Behandlung der Schizophrenie sowie Mittel zur Verwendung in diesem Verfahren
GB9911037D0 (en) * 1999-05-13 1999-07-14 Micap Limited Nicotine delivery service
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3760806A (en) * 1971-01-13 1973-09-25 Alza Corp Helical osmotic dispenser with non-planar membrane
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3764984A (en) * 1972-01-28 1973-10-09 Benz G Information coding system
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3870794A (en) * 1974-02-20 1975-03-11 Foundation For Behavioral Rese Treatment of certain emotional disorders with nicotine compounds
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
ATE12731T1 (de) * 1979-01-11 1985-05-15 Key Pharma Polymere diffusionsmatrix und verfahren zu deren herstellung.
US4278679A (en) * 1980-05-01 1981-07-14 Chromalloy American Corporation Combination of two or more drugs in a single dosage form wherein one of the drugs is a physostigmine compound
US4278667A (en) * 1980-06-02 1981-07-14 Chromalloy American Corporation Method of treating tardive dyskinesia by oral dosage form of a physostigmine compound
DK90883A (da) * 1982-03-18 1983-09-19 Merck & Co Inc Beholder til osmotisk afgivelse af et stof eller en stofblanding
ZA836627B (en) * 1982-10-08 1984-05-30 Verex Lab Constant release rate solid oral dosage formulation of pharmaceutical compounds having a high degree of water solubility
GR79143B (ja) * 1983-01-05 1984-10-02 Biomeasure Inc
GB2142822B (en) * 1983-06-29 1987-02-11 Alec Stanley Walter Shaw Nicotine lozenges
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine

Also Published As

Publication number Publication date
US4680172A (en) 1987-07-14
FR2578421B1 (fr) 1990-01-19
FR2602974B1 (fr) 1991-02-22
SE9003219L (sv) 1992-04-10
JPH0834733A (ja) 1996-02-06
IL78025A0 (en) 1986-07-31
BE904342A (fr) 1986-09-04
SE9003219D0 (sv) 1990-10-09
AU5427586A (en) 1986-10-16
JPS61267517A (ja) 1986-11-27
ZA861582B (en) 1986-10-29
DK99086D0 (da) 1986-03-04
JPH0780769B2 (ja) 1995-08-30
SE8600947L (sv) 1986-09-06
GB2171906A (en) 1986-09-10
CH667993A5 (de) 1988-11-30
IT1208735B (it) 1989-07-10
FR2578421A1 (fr) 1986-09-12
FR2602974A1 (fr) 1988-02-26
LU86324A1 (de) 1986-09-02
GB2171906B (en) 1989-01-25
ATA55386A (de) 1991-05-15
DK99086A (da) 1986-09-06
SE8600947D0 (sv) 1986-03-03
IT8647707A0 (it) 1986-03-03
CA1274175A (en) 1990-09-18
DE3606892A1 (de) 1986-09-18

Similar Documents

Publication Publication Date Title
NL8600555A (nl) Farmaceutische formuleringen en werkwijze voor de behandeling van geheugenstoornissen.
US4965074A (en) Method of treating memory impairment
US4765985A (en) Devices and methods for treating memory impairment
Peach et al. Role of calcium in endothelium-dependent relaxation of arterial smooth muscle
US5612056A (en) Transdermal formulations
Lückhoff et al. Characterization of vascular relaxant factor released from cultured endothelial cells.
GB2098865A (en) Topical pharmaceutical compositions
Mark et al. The passage of thiobarbiturates and their oxygen analogs into brain
US4777047A (en) Transdermal application form of calcium antagonists
US6127385A (en) Method of treating depression using l-threo-methylphenidate
KR20010050225A (ko) 포유동물에서의 니코틴 탐닉의 예방 및 치료를 위한 약학조성물
Okamoto et al. Enhanced penetration of mitomycin C through hairless mouse and rat skin by enhancers with terpene moieties
Furman The hypoglycaemic effect of 5-hydroxytryptophan
Elyan et al. Evaluation of the effect of different fatty acids on the percutaneous absorption of metaproterenol sulfate
US3932653A (en) Composition and method for topical administration of griseofulvin
GB2162745A (en) Nasal compositions
KR100457850B1 (ko) 활성 물질의 방출성이 큰 겔형 항진균성 약제학적 제제
Bova et al. Vasorelaxant properties of norbormide, a selective vasoconstrictor agent for the rat microvasculature
Levy et al. Absorption kinetics of a series of local anesthetics from rat subcutaneous tissue. I
FI105917B (fi) Menetelmä terapeuttisesti aktiivisen 5-kloori-2,3-dihydro-2,2-dimetyylibentsofuraani-7-karboksyylihappo-oktahydro-3-hydroksi-2,6-metano-2H-kinolitsin-8-yyliesterin valmistamiseksi
Mahjour et al. Effects of propylene glycol diesters of caprylic and capric acids (Miglyol® 840) and ethanol binary systems on in vitro skin permeation of drugs
US5248674A (en) Percutaneous administration of 3'-azide'-deoxythymidine
US4973708A (en) 3-hydroxy-N-methylpyrrolidone and preparation thereof
US4666926A (en) Transdermal formulations
Dorato et al. Effect of lysine and diethanolamine—rutin on blood levels, withdrawal reaction and acute toxicity of ethanol in mice

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
CNR Transfer of rights (patent application after its laying open for public inspection)

Free format text: NOVARTIS AG

BN A decision not to publish the application has become irrevocable